SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival

Osnat Ashur-Fabian, Orly Perl, Gila Lilling, Mati Fridkin, Illana Gozes*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


The current study explored whether the neuroprotective effects of vasoactive intestinal peptide (VIP) and its analog Stearyl-Nle17-VIP (SNV) were mediated through cGMP. SNV, was previously found to be 100-fold more potent than VIP in providing neuroprotection. Neuronal survival was assessed in rat cerebral cortical cultures. A cGMP antagonist (RP-8-pCPT-cGMPS, 10-12-10-9 M) reduced the number of surviving neurons (40-60%), this decline was spared in the presence of SNV (10-13 M). A cGMP agonist (Sp-8-pCPT-cGMPS, 10-14-10-8 M) and SNV (10-16-10-8 M) both provided significant neuroprotection against 10-12 M of the cGMP antagonist. Immunoassays indicated that SNV induced increases in cGMP (two-threefold) in these cultures, whereas VIP was 1000-fold less potent. These results implicate cGMP as a second messenger for VIP/SNV-mediated effects on neuronal survival. Copyright (C) 1999 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)629-633
Number of pages5
Issue number5
StatePublished - Jun 1999


FundersFunder number
US–Israel Binational Science Foundation


    • Cyclic guanosine monophosphate (cGMP)
    • Enzymeimmunoassays (EIA)
    • Immunocytochemistry
    • Neuronal survival
    • Radioimmunoassays (RIA)
    • Stearyl-Nle-VIP (SNV)
    • Vasoactive intestinal peptide (VIP)


    Dive into the research topics of 'SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival'. Together they form a unique fingerprint.

    Cite this